ESMO Breast Cancer：New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

Simcere Zaiming will Present 8 Research Abstracts at the 2023 AACR Annual Meeting

Simcere Zaiming Doses First Patient in Phase 1 Trial of SIM0348, a TIGIT/PVRIG Bi-specific Antibody

Simcere Zaiming Announces Clinical Collaboration to Evaluate SIM0235, a TNFR2 Monoclonal Antibody, in Combination with KEYTRUDA^® (pembrolizumab) in a Phase 1 Trial in Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Academic Meeting of Domestic and Overseas Experts — SANBEXIN^® Opens the Door to Brain Cell Protection

Simcere Zaiming Enrolls First Patient in Phase 1 Trial of SIM0237, an anti-PD-L1/IL-15 Bi-functional Fusion Protein

XIANNUOXIN^®: The Key to Pandemic Prevention and Control for Vulnerable Populations

NMPA Commissioner Jiao Hong Investigated the Quality Assurance and Supply Guarantee of the Anti-COVID-19 Innovative Drug XIANNUOXIN^®

COSELA^®, the first and only proactive multilineage myeloprotection therapy for chemotherapy-induced myelosuppression, was launched in China, greatly improving the accessibility of imported drugs urgently needed in clinical practice

XIANNUOXIN^® is put into production and launched today, contributing to China's economic development and the public's health